Marie-Sophie Minot-This

Dr. Marie-Sophie Minot-This

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMarie-Sophie Minot-This
Marie-Sophie Minot-This
PBPascaline BOUDOU-ROUQUETTE
Pascaline BOUDOU-ROUQUETTE
AJAnne Jouinot
Anne Jouinot
SPSixtine de Percin
Sixtine de Percin
DBDavid Balakirouchenane
David Balakirouchenane
JAJérôme Alexandre
Jérôme Alexandre
Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed to define the specific threshold of PAZ trough concentration (Cmin) associated with better progression-free survival (PFS) in STS patients. Methods: In this observational study, PAZ Cmin was monitored over the treatment course. For the primary endpoint, the 3-month PFS in STS was analyzed with logistic regression. Second, we performed exposure–overall survival (OS) (Cox model plus Kaplan–Meier analysis/log-rank test) and exposure–toxicity analyses. Results: Ninety-five STS patients were eligible for pharmacokinetic/pharmacodynamic (PK/PD) assessment. In the multivariable analysis, PAZ Cmin < 27 mg/L was independently associated with a risk of progression at 3 months (odds ratio (OR) 4.21, 95% confidence interval (CI) (1.47–12.12), p = 0.008). A higher average of PAZ Cmin over the first 3 months was associated with a higher risk of grade 3–4 toxicities according to the NCI-CTCAE version 5.0 (OR 1.07 per 1 mg/L increase, CI95 (1.02–1.13), p = 0.007). Conclusion: PAZ Cmin ≥ 27 mg/L was independently associated with improved 3-month PFS in STS patients. Pharmacokinetically-guided dosing could be helpful to optimize the clinical management of STS patients in daily clinical practice.

16 June 2021 in Bulletin du Cancer
Verified
Journal Article
Closed access
MMMarie-Sophie Minot-This
Marie-Sophie Minot-This
ABAudrey Bellesoeur
Audrey Bellesoeur

5 April 2022
Verified
Preprint
Open access
PDF file
MMMarie-Sophie Minot-This
Marie-Sophie Minot-This
PBPascaline Boudou
Pascaline Boudou
AJAnne Jouinot
Anne Jouinot
SPSixtine De Percin
Sixtine De Percin
DBDavid Balakirouchenane
David Balakirouchenane
JAJerôme Alexandre
Jerôme Alexandre
Background. Pazopanib is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. In order to improve its clinical use, this study aimed to define specific threshold of pazopanib trough concentration (Cmin) associated with better progression free survival in STS patients. Methods. In this observational study, pazopanib Cmin was monitored over the treatment course. For the primary endpoint, the 3-month PFS in STS was analyzed with logistic regression. Secondary, we performed exposure–overall survival (OS) in STS (Cox model plus Kaplan–Meier analysis/ log-rank test) and exposure-toxicity analyses. Results. One hundred eighteen patients (95 STS and 23 BS) were eligible for PK/PD assessment. In multivariable analysis, pazopanib Cmin < 27 mg/L was independently associated with a risk of progression at 3 months (OR 4.21, 95% CI [1.47-12.12], p = 0.008). OS was not statistically longer between patients with Cmin > 27 mg/L and those with Cmin < 27 mg/L (log-rank p = 0.07). A higher average of PAZ Cmin over the first 3 months of treatment was associated with a higher risk of grades 3-4 toxicities (40.0 vs 30.5 mg/L (OR 1.05, IC95 [1.01-1.09], p = 0.01) Conclusion. Pazopanib Cmin ≥ 27 mg/L was independently associated with improved 3-month PFS in a large cohort of STS patients. Pharmacokinetically-guided dosing could be helpful to optimize clinical management of STS patients in daily clinical practice.

6 March 2023 in CNS Oncology
Verified
Journal Article
Open access
MMMarie-Sophie Minot-This
Marie-Sophie Minot-This
TGThomas Grinda
Thomas Grinda
NENicolas Epaillard
Nicolas Epaillard
DGDavid Guyon
David Guyon
RJRita El Jawiche
Rita El Jawiche
BPBarbara Pistilli
Barbara Pistilli
We report the case of a patient with metastatic breast cancer who presented with an orthostatic headache. After a comprehensive diagnostic workup including MRI and lumbar puncture, we maintained th...

2 February 2021 in Bulletin du Cancer
Verified
Journal Article
Closed access
MMMarie-Sophie Minot-This
Marie-Sophie Minot-This
JEJulien Edeline
Julien Edeline

3 June 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CDColine Ducrot
Coline Ducrot
DDDerek Dinart
Derek Dinart
MBMaeva Bonneau
Maeva Bonneau
MPMax Piffoux
Max Piffoux
MMMarie-Sophie Minot-This
Marie-Sophie Minot-This
MTMaud Toulmonde
Maud Toulmonde
Metastatic Ewing sarcoma (MES) has a poor prognosis. This multicenter observational study provides real‐world data on treatment patterns of patients with MES in France. Treatment characteristics, outcomes such as time to next treatment (TTNT) and overall survival (OS), and prognostic factors of patients aged ≥ 12 years treated for a MES in 11 French reference network centers were retrieved from our national database. From 2008 to 2018, 156 patients with MES were included: 82 were metastatic at diagnosis (upfront metastatic cohort), 74 had developed secondary metastases after treatment of a localized disease (metastatic relapse cohort). 94% of patients received systemic treatment, with a median of three lines (1–11), 61% had at least one loco‐regional procedure and 42% of patients participated in a clinical trial in the metastatic setting. Median OS from metastatic diagnosis was 20.3 months [95% CI 14.0; 27.7] in the metastatic relapse cohort and 31.4 months [95% CI 26.5; 42.5] in the upfront metastatic cohort ( p = 0.02). Median TTNT in first metastatic line was 16.8 months [95% CI 12.9; 21.3] in the upfront metastatic cohort and 7.4 months [95% CI 5.0; 11.1] in the metastatic relapse cohort, 5.8 months [95% CI 3.6; 7.3] in 2nd line and 3.8 months [95% CI 2.8; 5.7] in 3rd line, without significant difference between cohorts and treatment regimens. Patients with upfront MES have a longer OS than patients with relapsing disease, mainly due to first metastatic line dose‐dense polychemotherapy and loco‐regional procedures in selected patients. Main regimens used at relapse are associated with the same range of benefit and survival, while TKIs such as regorafenib or cabozantinib have modest activity. Inclusion in clinical trials should be prioritized.